Últimas noticias sobre Allurion Technologies (NYSE:ALUR) Bolsa

Allurion Technologies

Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Movimiento de acciones

News

Intraday Update

Markets

Movers

Trading Ideas

ALUR

AUID

BHAT

BNTC

GCTK

INNV

MCVT

OUST

PNBK

PSTV

RVSB

TNMG

USAR

XHLD

Ouster sorprende con resultados mejores de lo esperado y sus acciones suben un 8,95%. Descubre las acciones que dominan el premercado.

Las acciones de Ouster (OUST) suben un 9%; Aquí están 20 acciones que se mueven en el premercado de EE.UU.

Pre-Market Outlook

ACON

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Explora los movimientos más destacados del pre-mercado, incluyendo el aumento del 23% en Logility y más sorpresas.

Acciones de Logility Supply Chain (LGTY) suben un 23%; 20 acciones que se mueven en el premercado de EE.UU.

Analyst Color

Equities

Market Summary

Futures

Analyst Ratings

ETFs

ISRG

STBX

Los futuros de acciones cayeron tras la decisión del BOJ de subir tasas al 0,5%. Analiza el impacto en los mercados.

Futuros de EE.UU. caen tras aumento de tasas del Banco de Japón: Análisis y previsiones clave

Allurion Technologies Inc

Allurion Technologies, Inc. Warrants, each whole warrant exercisable to purchase 1.420455 shares of common stock at an exercise price of $8.10 per share of common stock

<h3>Gainers</h3>
<ul>
<li><strong>Vince Holding</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) stock moved upwards by 17.6% to $1.94 during Friday's after-market session. The company's market cap stands at $24.4 million. </li>
<li><strong>ATA Creativity Global</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACG#NASDAQ">AACG</a>) stock moved upwards by 8.98% to $0.97. The company's market cap stands at $30.5 million. </li>
<li><strong>Birks Group</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) stock rose 6.25% to $0.96. The market value of their outstanding shares is at $18.3 million. </li>
<li><strong>Dave &amp; Buster's Enter</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) stock increased by 5.68% to $20.99. The market value of their outstanding shares is at $724.4 million. </li>
<li><strong>United Homes Gr</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) shares moved upwards by 5.55% to $1.9. The market value of their outstanding shares is at $111.3 million. </li>
<li><strong>Jeffs Brands</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) shares rose 5.35% to $0.86. The company's market cap stands at $1.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>E-Home Household Service</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) stock decreased by 10.4% to $0.09 during Friday's after-market session. </li>
<li><strong>TCTM Kids IT Education</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) stock declined by 10.05% to $0.63. The market value of their outstanding shares is at $6.2 million. </li>
<li><strong>SharpLink Gaming</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares fell 7.83% to $3.3. The company's market cap stands at $1.8 million. </li>
<li><strong>Jiade</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) shares decreased by 5.61% to $0.5. The market value of their outstanding shares is at $12.2 million. </li>
<li><strong>Live Ventures</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVE#NASDAQ">LIVE</a>) shares fell 4.66% to $19.46. The market value of their outstanding shares is at $60.4 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li><strong>INNEOVA Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INEO#NASDAQ">INEO</a>) shares decreased by 4.62% to $1.24. The market value of their outstanding shares is at $12.2 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AACG

INEO

JDZG

JFBR

LIVE

PLAY

SBET

VNCE

12 Consumer Discretionary Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Polyrizon</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock moved upwards by 57.1% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $3.9 million. </li>
<li><strong>NuCana</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares rose 17.35% to $0.05. </li>
<li><strong>Voyager Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) stock moved upwards by 13.56% to $3.6. The market value of their outstanding shares is at $199.2 million. The company's, Q1 earnings came out 3 days ago. </li>
<li><strong>Shuttle Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock moved upwards by 9.24% to $0.25. The market value of their outstanding shares is at $1.5 million. </li>
<li><strong>Gelteq</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) stock moved upwards by 8.75% to $1.49. The market value of their outstanding shares is at $14.0 million. </li>
<li><strong>CARISMA Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) stock increased by 8.08% to $0.21. The market value of their outstanding shares is at $8.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>SCWorx</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock declined by 12.9% to $0.53 during Friday's after-market session. The company's market cap stands at $1.2 million. </li>
<li><strong>Envoy Medical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock fell 8.88% to $1.54. The company's market cap stands at $32.8 million. </li>
<li><strong>Matinas BioPharma Hldgs</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) shares decreased by 6.39% to $0.66. The market value of their outstanding shares is at $3.3 million. </li>
<li><strong>CNS Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares declined by 6.2% to $1.06. The market value of their outstanding shares is at $3.1 million. </li>
<li><strong>Xencor</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) shares declined by 5.53% to $7.87. The market value of their outstanding shares is at $560.1 million. The company's, Q1 earnings came out 2 days ago. </li>
<li><strong>AquaBounty Techs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock fell 5.38% to $0.65. The company's market cap stands at $2.5 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CARM

CNSP

Envoy Medical, Inc. - Class A Common Stock

COCH

GELS

MTNB

NCNA

PLRZ

SHPH

VYGR

WORX

XNCR

12 Health Care Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Forward Air</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) stock increased by 11.2% to $18.14 during Friday's after-market session. The company's market cap stands at $551.8 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li><strong>C3is</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISS#NASDAQ">CISS</a>) stock moved upwards by 9.3% to $4.11. The company's market cap stands at $2.9 million. </li>
<li><strong>Volato Group</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) shares moved upwards by 8.73% to $2.48. The company's market cap stands at $4.5 million. </li>
<li><strong>PS International Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares moved upwards by 8.51% to $0.33. The market value of their outstanding shares is at $8.0 million. </li>
<li><strong>Aeries Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AERT#NASDAQ">AERT</a>) shares moved upwards by 7.31% to $0.75. The market value of their outstanding shares is at $33.4 million. </li>
<li><strong>LanzaTech Global</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) stock rose 6.12% to $0.23. The company's market cap stands at $45.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Vast Renewables</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares declined by 15.1% to $0.12 during Friday's after-market session. The market value of their outstanding shares is at $3.5 million. </li>
<li><strong>Solidion Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) stock decreased by 8.31% to $0.1. The market value of their outstanding shares is at $12.9 million. </li>
<li><strong>Click Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) stock decreased by 7.13% to $0.23. The company's market cap stands at $7.3 million. </li>
<li><strong>Nuvve Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) shares declined by 6.48% to $2.6. The company's market cap stands at $7.9 million. </li>
<li><strong>Momentus</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) shares fell 5.99% to $1.57. The company's market cap stands at $8.2 million. </li>
<li><strong>JE Cleantech Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) stock fell 5.19% to $1.28. The market value of their outstanding shares is at $6.7 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Advanced Environmental Recycling Technologies

AERT

CISS

CLIK

FWRD

JCSE

LNZA

MNTS

NVVE

PSIG

SOAR

VSTE

12 Industrials Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Next Technology Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) stock moved upwards by 74.6% to $4.12 during Friday's after-market session. The market value of their outstanding shares is at $28.7 million. As per the press release, Q1 earnings came out today. </li>
<li><strong>Oblong</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) shares increased by 30.82% to $3.65. The company's market cap stands at $4.2 million. </li>
<li><strong>Wellchange Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) shares rose 7.87% to $0.29. The company's market cap stands at $13.3 million. </li>
<li><strong>Argo Blockchain</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) stock increased by 6.07% to $0.39. The company's market cap stands at $24.6 million. </li>
<li><strong>Lightwave Logic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWLG#NASDAQ">LWLG</a>) shares rose 4.95% to $1.06. The market value of their outstanding shares is at $132.0 million. </li>
<li><strong>SMX (Security Matters)</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares rose 4.6% to $1.59. The company's market cap stands at $4.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Abits Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) stock declined by 33.1% to $5.63 during Friday's after-market session. The market value of their outstanding shares is at $13.3 million. </li>
<li><strong>Infobird Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) shares fell 18.31% to $1.25. The company's market cap stands at $10.2 million. </li>
<li><strong>Research Frontiers</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFR#NASDAQ">REFR</a>) stock declined by 5.04% to $1.51. The company's market cap stands at $50.8 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li><strong>Pixelworks</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) shares decreased by 5.0% to $0.53. The market value of their outstanding shares is at $33.0 million. </li>
<li><strong>Mitek Systems</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITK#NASDAQ">MITK</a>) stock fell 4.93% to $9.26. The company's market cap stands at $418.9 million. The company's, Q2 earnings came out yesterday. </li>
<li><strong>Ascent Solar Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTI#NASDAQ">ASTI</a>) shares fell 4.73% to $1.81. The market value of their outstanding shares is at $3.0 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ABTS

ARBK

ASTI

IFBD

LWLG

MITK

Next Technology Holding Inc. - Ordinary Shares

NXTT

OBLG

REFR

12 Information Technology Stocks Moving In Friday's After-Market Session

<p>JP Morgan  analyst Christopher Horvers   maintains BJ's Wholesale Club Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) with a Neutral and raises the price target from $109 to $123.</p>


Price Target

JP Morgan Maintains Neutral on BJ's Wholesale Club Hldgs, Raises Price Target to $123

Offerings

STWD

Starwood Property Trust Files For Mixed Shelf; Size Not Disclosed

Biotech

General

APLT

Applied Therapeutics To Present Full 12-Month Clinical Results From The INSPIRE Phase 3 Trial Of Govorestat In A Late-Breaking Abstract Selected For Oral Presentation At The Peripheral Nerve Society 2025 Annual Meeting, Being Held May 17-20, 2025 In Edinburgh, Scotland

<p>JP Morgan  analyst Rachel Vatnsdal   maintains 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) with a Neutral and lowers the price target from $12 to $9.</p>


JP Morgan Maintains Neutral on 10x Genomics, Lowers Price Target to $9

<p><strong>Radiant Logistics</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RLGT#AMEX">RLGT</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Radiant Logistics will report an <strong>earnings per share</strong> (EPS) of $0.05. </p>
<p>Radiant Logistics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.12, leading to a 1.7% increase in the share price on the subsequent day.</p>
<p>Here's a look at Radiant Logistics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.10</td>
<td>0.14</td>
<td>0.10</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.22</td>
<td>0.16</td>
<td>0.14</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-4.0%</td>
<td>3.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746824597_0.png" alt="eps graph" /></p>
<h3>Performance of Radiant Logistics Shares</h3>
<p>Shares of Radiant Logistics were trading at $6.03 as of May 08. Over the last 52-week period, shares are up 21.21%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/RLGT/earnings"><strong>To track all earnings releases for Radiant Logistics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

RLGT

Earnings Outlook For Radiant Logistics

<p>Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Xtant Medical Hldgs to report an <strong>earnings per share</strong> (EPS) of $-0.02.</p>
<p>Investors in Xtant Medical Hldgs are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.00, leading to a 4.39% drop in the share price on the subsequent day.</p>
<p>Here's a look at Xtant Medical Hldgs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.02</td>
<td>-0.02</td>
<td>-0.02</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.02</td>
<td>-0.04</td>
<td>-0.03</td>
<td>-0.03</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>-13.0%</td>
<td>-5.0%</td>
<td>-12.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746824589_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Xtant Medical Hldgs were trading at $0.537 as of May 08. Over the last 52-week period, shares are down 36.92%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/XTNT/earnings"><strong>To track all earnings releases for Xtant Medical Hldgs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


XTNT

A Glimpse of Xtant Medical Hldgs's Earnings Potential

<p>JP Morgan  analyst Reginald Smith   maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Overweight and lowers the price target from $74 to $69.</p>


AFRM

JP Morgan Maintains Overweight on Affirm Holdings, Lowers Price Target to $69

<p>Pangaea Logistics Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANL#NASDAQ">PANL</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Pangaea Logistics Solns will report an <strong>earnings per share</strong> (EPS) of $-0.10.</p>
<p>Investors in Pangaea Logistics Solns are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.01, leading to a 12.19% increase in the share price on the subsequent day.</p>
<p>Here's a look at Pangaea Logistics Solns's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.17</td>
<td>0.27</td>
<td>0.15</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.16</td>
<td>0.24</td>
<td>0.10</td>
<td>0.14</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>12.0%</td>
<td>-7.000000000000001%</td>
<td>-1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746824581_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Pangaea Logistics Solns were trading at $4.07 as of May 08. Over the last 52-week period, shares are down 48.52%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/PANL/earnings"><strong>To track all earnings releases for Pangaea Logistics Solns visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PANL

Pangaea Logistics Solns's Earnings: A Preview

<p><strong>Century Casinos</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Century Casinos will report an <strong>earnings per share</strong> (EPS) of $-0.45. </p>
<p>Investors in Century Casinos are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS missed by $0.20 in the last quarter, leading to a 0.52% drop in the share price on the following day.</p>
<p>Here's a look at Century Casinos's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.49</td>
<td>-0.24</td>
<td>-0.28</td>
<td>-0.42</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.69</td>
<td>-0.26</td>
<td>-1.36</td>
<td>-0.45</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>7.000000000000001%</td>
<td>-0.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746824560_0.png" alt="eps graph" /></p>
<h3>Market Performance of Century Casinos's Stock</h3>
<p>Shares of Century Casinos were trading at $1.49 as of May 08. Over the last 52-week period, shares are down 48.1%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CNTY/earnings"><strong>To track all earnings releases for Century Casinos visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CNTY

Century Casinos's Earnings: A Preview

<p><strong>Imunon</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Imunon will report an <strong>earnings per share</strong> (EPS) of $-0.36. </p>
<p>Investors in Imunon are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.13 in the last quarter, leading to a 9.96% increase in the share price on the following day.</p>
<p>Here's a look at Imunon's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.36</td>
<td>-0.40</td>
<td>-0.60</td>
<td>-0.57</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.23</td>
<td>-0.34</td>
<td>-0.51</td>
<td>-0.52</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>10.0%</td>
<td>-3.0%</td>
<td>5.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746824551_0.png" alt="eps graph" /></p>
<h3>Market Performance of Imunon's Stock</h3>
<p>Shares of Imunon were trading at $0.835 as of May 08. Over the last 52-week period, shares are down 45.95%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/IMNN/earnings"><strong>To track all earnings releases for Imunon visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


IMNN

Imunon's Earnings: A Preview

<p>Quanterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Quanterix to report an <strong>earnings per share</strong> (EPS) of $-0.69.</p>
<p>Quanterix bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company missed EPS by $0.08, which was followed by a 1.79% drop in the share price the next day.</p>
<p>Here's a look at Quanterix's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.22</td>
<td>-0.27</td>
<td>-0.26</td>
<td>-0.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.30</td>
<td></td>
<td>-0.25</td>
<td>-0.26</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-18.0%</td>
<td>-15.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Market Performance of Quanterix's Stock</h3>
<p>Shares of Quanterix were trading at $5.51 as of May 08. Over the last 52-week period, shares are down 68.68%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analysts' Perspectives on Quanterix</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Quanterix.</p>
<p>A total of 3 analyst ratings have been received for Quanterix, with the consensus rating being Buy. The average one-year price target stands at $13.67, suggesting a potential 148.09% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of MaxCyte, Maravai LifeSciences and Rapid Micro Biosystems, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for MaxCyte, with an average 1-year price target of $9.0, suggesting a potential 63.34% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Maravai LifeSciences, with an average 1-year price target of $4.62, suggesting a potential 16.15% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Rapid Micro Biosystems, with an average 1-year price target of $8.0, suggesting a potential 45.19% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for MaxCyte, Maravai LifeSciences and Rapid Micro Biosystems, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quanterix</td>
<td>Buy</td>
<td>9.32%</td>
<td>$21.11M</td>
<td>-3.48%</td>
</tr>
<tr>
<td>MaxCyte</td>
<td>Buy</td>
<td>-44.51%</td>
<td>$6.41M</td>
<td>-5.05%</td>
</tr>
<tr>
<td>Maravai LifeSciences</td>
<td>Neutral</td>
<td>-23.92%</td>
<td>$18.96M</td>
<td>-7.80%</td>
</tr>
<tr>
<td>Rapid Micro Biosystems</td>
<td>Outperform</td>
<td>29.68%</td>
<td>$981K</td>
<td>-12.10%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Quanterix ranks highest in revenue growth among its peers. It also leads in gross profit margin. However, it has the lowest return on equity.</p>
<h3>Discovering Quanterix: A Closer Look</h3>
<p>Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs &amp; Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.</p>
<h3>Key Indicators: Quanterix's Financial Health</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Quanterix's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>9.32%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Quanterix's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-34.09%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-3.48%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Quanterix's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-2.84%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.11</strong>, Quanterix adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/QTRX/earnings"><strong>To track all earnings releases for Quanterix visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


QTRX

Earnings Outlook For Quanterix

<p>Natural Gas Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGS#NYSE">NGS</a>) is preparing to release its quarterly earnings on Monday, 2025-05-12. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Natural Gas Services Gr to report an <strong>earnings per share</strong> (EPS) of $0.26.</p>
<p>Natural Gas Services Gr bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company missed EPS by $0.02, which was followed by a 7.62% drop in the share price the next day.</p>
<p>Here's a look at Natural Gas Services Gr's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.25</td>
<td>0.23</td>
<td>0.29</td>
<td>0.21</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.23</td>
<td>0.40</td>
<td>0.34</td>
<td>0.41</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-8.0%</td>
<td>2.0%</td>
<td>11.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746824534_0.png" alt="eps graph" /></p>
<h3>Market Performance of Natural Gas Services Gr's Stock</h3>
<p>Shares of Natural Gas Services Gr were trading at $20.11 as of May 08. Over the last 52-week period, shares are down 9.15%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Observations about Natural Gas Services Gr</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Natural Gas Services Gr.</p>
<p>Natural Gas Services Gr has received a total of 1 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $32.0, the consensus suggests a potential 59.12% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Oil States International, DMC Glb and Tetra Technologies, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Oil States International, with an average 1-year price target of $4.0, suggesting a potential 80.11% downside.</li>
<li>Analysts currently favor an Neutral trajectory for DMC Glb, with an average 1-year price target of $9.0, suggesting a potential 55.25% downside.</li>
<li>Analysts currently favor an Buy trajectory for Tetra Technologies, with an average 1-year price target of $5.38, suggesting a potential 73.25% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Oil States International, DMC Glb and Tetra Technologies, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natural Gas Services Gr</td>
<td>Buy</td>
<td>12.25%</td>
<td>$14.51M</td>
<td>1.13%</td>
</tr>
<tr>
<td>Oil States International</td>
<td>Neutral</td>
<td>-4.38%</td>
<td>$25.24M</td>
<td>0.45%</td>
</tr>
<tr>
<td>DMC Glb</td>
<td>Neutral</td>
<td>-4.54%</td>
<td>$41.20M</td>
<td>0.29%</td>
</tr>
<tr>
<td>Tetra Technologies</td>
<td>Buy</td>
<td>4.09%</td>
<td>$42.91M</td>
<td>1.54%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Natural Gas Services Gr ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.</p>
<h3>Delving into Natural Gas Services Gr's Background</h3>
<p>Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.</p>
<h3>Unraveling the Financial Story of Natural Gas Services Gr</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Natural Gas Services Gr displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>12.25%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Natural Gas Services Gr's net margin is impressive, surpassing industry averages. With a net margin of <strong>7.05%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Natural Gas Services Gr's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.13%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.58%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Natural Gas Services Gr's debt-to-equity ratio surpasses industry norms, standing at <strong>0.67</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/NGS/earnings"><strong>To track all earnings releases for Natural Gas Services Gr visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Natural Gas Services Gr's Earnings: A Preview

<p>Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Regenxbio will report an <strong>earnings per share</strong> (EPS) of $0.34.</p>
<p>The market awaits Regenxbio's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.07, leading to a 2.6% increase in the share price the following trading session.</p>
<p>Here's a look at Regenxbio's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.08</td>
<td>-1.12</td>
<td>-1.29</td>
<td>-1.26</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.01</td>
<td>-1.17</td>
<td>-1.05</td>
<td>-1.38</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>19.0%</td>
<td>-2.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746824517_0.png" alt="eps graph" /></p>
<h3>Regenxbio Share Price Analysis</h3>
<p>Shares of Regenxbio were trading at $7.15 as of May 08. Over the last 52-week period, shares are down 52.22%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Insights Shared by Analysts on Regenxbio</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Regenxbio.</p>
<p>Regenxbio has received a total of 8 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $32.0, the consensus suggests a potential 347.55% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of  and Myriad Genetics, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Myriad Genetics, with an average 1-year price target of $13.67, suggesting a potential 91.19% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for  and Myriad Genetics, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regenxbio</td>
<td>Buy</td>
<td>-4.50%</td>
<td>$14.90M</td>
<td>-18.25%</td>
</tr>
<tr>
<td>Myriad Genetics</td>
<td>Neutral</td>
<td>7.12%</td>
<td>$150.90M</td>
<td>-5.93%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Regenxbio is at the bottom for Revenue Growth and Gross Profit, with negative percentages. It is also at the bottom for Return on Equity, with a negative percentage.</p>
<h3>Delving into Regenxbio's Background</h3>
<p>Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.</p>
<h3>Understanding the Numbers: Regenxbio's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Challenges:</strong> Regenxbio's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-4.5%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Regenxbio's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-241.28%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Regenxbio's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-18.25%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Regenxbio's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-10.39%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Regenxbio's debt-to-equity ratio surpasses industry norms, standing at <strong>0.32</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/RGNX/earnings"><strong>To track all earnings releases for Regenxbio visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


RGNX

What to Expect from Regenxbio's Earnings

<p><strong>Superior Industries Intl</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Superior Industries Intl will report an <strong>earnings per share</strong> (EPS) of $-0.37. </p>
<p>The announcement from Superior Industries Intl is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company missed EPS by $0.15, which was followed by a 4.95% increase in the share price the next day.</p>
<p>Here's a look at Superior Industries Intl's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.60</td>
<td>-0.15</td>
<td></td>
<td>-0.85</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.75</td>
<td>-1.24</td>
<td>-0.75</td>
<td>-0.75</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>5.0%</td>
<td>4.0%</td>
<td>-4.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Market Performance of Superior Industries Intl's Stock</h3>
<p>Shares of Superior Industries Intl were trading at $2.87 as of May 08. Over the last 52-week period, shares are down 23.47%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SUP/earnings"><strong>To track all earnings releases for Superior Industries Intl visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Glimpse of Superior Industries Intl's Earnings Potential

<p>Centuri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Centuri Holdings will report an <strong>earnings per share</strong> (EPS) of $-0.16.</p>
<p>Investors in Centuri Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company beat EPS by $0.02, leading to a 3.89% drop in the share price the following trading session.</p>
<p>Here's a look at Centuri Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.19</td>
<td>0.30</td>
<td>0.22</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.21</td>
<td>0.06</td>
<td>0.20</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>14.000000000000002%</td>
<td>0.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746824491_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Centuri Holdings were trading at $20.91 as of May 08. Over the last 52-week period, shares are down 13.71%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CTRI/earnings"><strong>To track all earnings releases for Centuri Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CTRI

Insights Ahead: Centuri Holdings's Quarterly Earnings

<p>Consolidated Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Consolidated Water Co to report an <strong>earnings per share</strong> (EPS) of $0.22.</p>
<p>Investors in Consolidated Water Co are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS missed by $0.17 in the last quarter, leading to a 6.7% drop in the share price on the following day.</p>
<p>Here's a look at Consolidated Water Co's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.28</td>
<td>0.25</td>
<td>0.34</td>
<td>0.38</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.11</td>
<td>0.31</td>
<td>0.26</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>5.0%</td>
<td>1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746824480_0.png" alt="eps graph" /></p>
<h3>Performance of Consolidated Water Co Shares</h3>
<p>Shares of Consolidated Water Co were trading at $23.34 as of May 08. Over the last 52-week period, shares are down 17.32%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CWCO/earnings"><strong>To track all earnings releases for Consolidated Water Co visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CWCO

A Look Ahead: Consolidated Water Co's Earnings Forecast

Press Releases

Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity

Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Allurion to Participate in Upcoming Investor Conferences

Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity

Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence

Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Comments

Allurion Technologies

Noticias

Últimas noticias sobre Allurion Technologies (NYSE:ALUR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL